Abstract
We investigated the correlation between obestatin and metabolic parameters and carotid intima-media thickness (IMT) in plasma of patients with type 2 diabetes mellitus (T2DM). We collected 103 patients aged from 60 to 83 years (69.26 ± 5.83 years) form January, 2007 to May, 2009. All patients were divided into normal glucose tolerance (NGT), impaired glucose tolerance (IGT), and T2DM according to the oral glucose tolerance test (OGTT). We found that higher levels of fasting insulin (Fins), fasting blood glucose, 2 h OGTT glucose, homeostasis model assessment of insulin resistance (HOMA-IR), low density lipoprotein cholesterol, glycated haemoglobin, and C-reactive protein (CRP), as well as lower obestatin level and higher intima-media thickness level (IMT), existed in T2DM group compared with NGT group and IGT group (P < 0.01). Also, obestatin level was independently associated with HOMA-IR and CRP, while IMT level was independently associated with HOMA-IR, triglyceride, Fins, and obestatin (P < 0.01), based on stepwise multiple regression analysis. Therefore, we deduced that the low level of plasma obestatin might be related to early arteriosclerosis in patients with T2DM via increasing IMT level, and elevated plasma obestatin levels might protect T2DM patients against carotid atherosclerosis to some extent.
Highlights
Type 2 diabetes mellitus (T2DM) is related to a significant increase in the risk of atherosclerosis [1]
There were no differences of age, diastolic blood pressure (DBP), systolic blood pressure (SBP), and Body mass index (BMI) levels between the three groups (P > 0.05)
Increased levels of fasting insulin (Fins), FPG, oral glucose tolerance test (OGTT)-2 h (2hPG), homeostasis model assessment of insulin resistance (HOMA-IR), HbA1c, LDL-C, and C-reactive protein (CRP) were detected in T2DM group compared with the other two groups (P < 0.01)
Summary
Type 2 diabetes mellitus (T2DM) is related to a significant increase in the risk of atherosclerosis [1]. In the past several years, clinical studies have shown that high mortality in patients with T2DM is due to cardiovascular disease [2]. With the development of blood glucose-lowering medications, such as lifestyle-directed interventions, insulin, sulfonylureas, and metformin, the number of treatment options available for T2DM has increased recently [7]. Rosiglitazone maleate targets insulin resistance to enhance the synthesis of glucose transporters and activate adipocyte differentiation, while metformin hydrochloride can promote the lowering glucose by reducing hepatic glucose production and enhance the gluconeogenesis; by increasing peripheral glucose uptake, the combination of two drugs is effective and safe in reducing hyperglycemia in patients with T2DM [8]. Numerous reviews on the management of T2DM have been published in recent years [9, 10], a clear pathway of therapy has not been confirmed
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
